Michael Holder
Known title: Chief Financial OfficerCIK: 0001515140
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
RCEL Gains Fair Value Lift After PermeaDerm Data and Q2 Beat. PermeaDerm data and a Q2 earnings beat lifted RCEL’s fair value. The news gave the stock a positive momentum boost. The lift comes as the company reports stronger‑than‑expected results and promising data from its PermeaDerm platform. The move is a short‑term reaction to the earnings beat and data release.
Transaction History
| CTKB | ▲ Buy | Option Exercise | 2,181 | — | 8/18/2026 | View on chart |
| CTKB | ▲ Buy | Option Exercise | 43,973 | — | 6/10/2026 | View on chart |
| CTKB | ▲ Buy | Option Exercise | 1,454 | — | 5/18/2026 | View on chart |
| CTKB | ▲ Buy | Option Exercise | 2,908 | — | 3/10/2026 | View on chart |
| CTKB | ▲ Buy | Option Exercise | 2,181 | — | 11/18/2025 | View on chart |
| CTKB | ▲ Buy | Option Exercise | 2,181 | $0 | 8/18/2025 | View on chart |
| CTKB | ▲ Buy | Option Exercise | 1,454 | — | 5/19/2025 | View on chart |
| CTKB | ▲ Buy | Option Exercise | 2,908 | — | 3/10/2025 | View on chart |
| CTKB | ▲ Buy | Option Exercise | 2,181 | — | 11/18/2024 | View on chart |
| CTKB | ▲ Buy | Option Exercise | 1,454 | — | 8/19/2024 | View on chart |
| RCEL | ▲ Buy | Grant | 35,950 | — | 7/1/2022 | View on chart |
| RCEL | ▲ Buy | Grant | 10,500 | — | 7/6/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Cytek spotlights spectral flow cytometry at ESCCA and ICCS conferences
Cytek Biosciences drew attention to the growing use of its spectral flow cytometry technology in clinical research at the ESCCA and ICCS conferences. The company also confirmed it will attend upcoming investor conferences. These are routine participation and awareness events rather than material business updates, with no new financial figures or product announcements disclosed. The current price sits within the stock's 52-week range of $3.28 to $6.18, below the average analyst target of $5.56.
Cytek spotlights spectral flow cytometry at ESCCA and ICCS conferences. Cytek Biosciences drew attention to the growing use of its spectral flow cytometry technology in clinical research at the ESCCA and ICCS conferences. The company also confirmed it will attend upcoming investor conferences. These are routine participation and awareness events rather than material business updates, with no new financial figures or product announcements disclosed. The current price sits within the stock's 52-week range of $3.28 to $6.18, below the average analyst target of $5.56.